Cholestech Corp. Sold for $326 Million

Inverness Medical Innovations will buy Cholestech Corp. for about $326 million.

MA-based company Inverness Medical Innovations will buy Cholestech Corp. in a stock deal worth about $326 million.

Waltham, MA-based Inverness will pay 0.43642 shares of its stock for each share of Hayward-based Cholestech’s common stock. The deal, based on Friday’s closing prices, values Cholestech at about $326 million.

Cholestech, led by CEO Warren Pinckert II, makes cholesterol tests and other medical diagnostic tests. Inverness also sells medical tests.

Covington & Associates was financial advisor to Inverness, and Foley Hoag LLP was its legal counsel. Savvian Advisors LLC was Cholestech’s financial advisor, and Wilson Sonsini Goodrich & Rosati PC was its legal counsel.

The deal requires Cholestech shareholder approval. It should close in the fall.

SOURCE:  SAN FRANCISCO BUSINESS TIMES

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters